B+
Overall grade
B+
Financial quality
SLEEPER STORY: The agency portal creating a distribution channel that scales without their sales team - SMB bookings up 100%+ via dozen+ partners bringing $5M+ revenue. This isn't just pharma growth, it's enterprise software distribution. Meanwhile, Jeff's personal focus shift to clinical AI plus the $26M Pathway acquisition signals bet-the-farm on becoming the Epocrates monopoly again. The binding constraint is AI monetization timeline - they're giving away premium features (Scribe, clinical reference) to build moats but haven't defined when they flip the switch to paid. 'I'm personally excited to be back working in clinical reference again. It's where I began my career with Epocrates over 20 years ago.' My view changes if they can't articulate AI revenue timeline by Q3 or if SMB agency growth stalls.
The 30-second version
- SLEEPER STORY: Agency portal driving 100% SMB growth - quiet enterprise distribution play
- Pathway acquisition ($26M cash + $37M equity) is actually a talent grab for medical AI corpus
- Revenue growth decelerating despite beat - guidance implies 11% growth vs 15% Q1
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Revenue | $138M (+17% YoY in Q4) | $146M (+15% YoY) |
| Adjusted EBITDA | $70M (50% margin in Q4) | $80M (55% margin) |
| Free Cash Flow | $97M (+56% YoY in Q4) | $60M (+52% YoY) |
| Net Revenue Retention | 119% TTM in Q4 | 118% TTM |
| $500K+ Customers | 116 customers (Q4) | 120 customers |
| Top 20 NRR | 123% in Q4 | 119% |
| Active Prescribers (Workflow) | 620K+ in Q4 | 630K |
| Newsfeed Users | 1M+ quarterly active in Q4 | 1M+ quarterly active |
Accountability tracked
7 new promises made5 narrative shifts flagged7 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →